Fesoterodine fumarate and the oxybutynin ring for the treatment of urinary incontinence in women.

Expert Opin Pharmacother

King's College Hospital, Denmark Hill, London, SE5 9RS , UK +0203 299 3568 ; +0203 299 3449 ;

Published: February 2014

Introduction: Urinary incontinence (UI) is a prevalent condition among women of all ages. It can have a significant negative impact on women's quality of life causing not only physical but also psychological distress.

Areas Covered: This article aims to provide a review of the pharmacology, efficacy, safety and tolerability of fesoterodine fumarate (the newest anticholinergic launched in the UK) and the oxybutynin vaginal ring (the newest route of drug delivery in development) in the treatment of urgency UI.

Expert Opinion: Fesoterodine is now a well-established treatment option; however, as with all oral anticholinergic agents its use is hindered by side effects. The efficacy of the oxybutynin ring has only been demonstrated in small studies. Larger clinical trials assessing the efficacy, tolerability and acceptability are required before appropriate recommendations can be made.

Download full-text PDF

Source
http://dx.doi.org/10.1517/14656566.2014.875158DOI Listing

Publication Analysis

Top Keywords

fesoterodine fumarate
8
oxybutynin ring
8
urinary incontinence
8
fumarate oxybutynin
4
ring treatment
4
treatment urinary
4
incontinence women
4
women introduction
4
introduction urinary
4
incontinence prevalent
4

Similar Publications

Article Synopsis
  • The study aimed to assess the risk of developing dementia associated with different anticholinergic drugs prescribed for overactive bladder among older adults in England.
  • Utilizing data from the Clinical Practice Research Datalink, researchers conducted a nested case-control study involving over 170,000 patients diagnosed with dementia, alongside matched controls without dementia.
  • Results indicated a slightly elevated risk of dementia (odds ratio of 1.18) linked to anticholinergic drug use, with a higher risk observed in men compared to women.
View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the link between various medications and drug-induced dry mouth, which impacts patients' quality of life.
  • Data was collected from the FDA's Adverse Event Reporting System from 2004 to 2024, analyzing 75,899 reports of dry mouth.
  • Findings indicated tiotropium bromide monohydrate was most commonly reported for causing dry mouth, while darifenacin had the highest risk; many implicated drugs lacked proper labeling for this side effect.
View Article and Find Full Text PDF

An Investigational Study on the Role of , and s Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers.

Pharmaceuticals (Basel)

September 2024

Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, Spain.

Fesoterodine is one of the most widely used antimuscarinic drugs to treat an overactive bladder. Fesoterodine is extensively hydrolyzed by esterases to 5-hydroxymethyl tolterodine (5-HMT), the major active metabolite. CYP2D6 and CYP3A4 mainly metabolize 5-HMT and are, therefore, the primary pharmacogenetic candidate biomarkers.

View Article and Find Full Text PDF

An update on the cognitive safety of antimuscarinics in the treatment of overactive bladder.

Expert Opin Drug Saf

October 2024

Department of Urology, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul, Korea.

Article Synopsis
  • Antimuscarinics are the primary medications for treating overactive bladder (OAB), especially in older adults, but their effects on cognitive function have raised concerns for over ten years.
  • A comprehensive review of studies was conducted to assess the cognitive safety of various antimuscarinic drugs, highlighting both recent and earlier findings.
  • While some medications like oxybutynin may impair cognition, others like darifenacin and fesoterodine show promise but need more research, suggesting careful monitoring and further studies are necessary for safer treatment options in patients, especially those with cognitive issues.
View Article and Find Full Text PDF

This narrative review discusses the relationship between anticholinergic medications and cognitive change specifically in patients with neurogenic lower urinary tract dysfunction (NLUTD). NLUTD is prevalent in various conditions, including spinal cord injury (SCI), spina bifida (SB), multiple sclerosis (MS), Parkinson's, stroke, and dementia and often requires anticholinergic overactive bladder (OAB) medications. In the general population, and among those with OAB, several studies have found a significant association between this class of medications and cognitive side effects, mostly when used for > 90 days.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!